Paper Details

  1. Home
  2. Paper Details

Citalopram in first episode schizophrenia: The DECIFER trial.

Author: ArdekaniBabak A, BelloIruma, CatherCorrine, DiminichErica, FanXiaoduo, FreudenreichOliver, GoffDonald C, HoltDaphne, LiChenxiang, TangYingying, TroxelAndrea, WangJijun, WorthingtonMichelle, WuRenrong, ZengBotao, ZhaoJingping

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study investigated the efficacy of citalopram as an add-on treatment for negative and depressive symptoms in patients with first-episode schizophrenia. The study found that citalopram may reduce negative symptoms, particularly in patients with longer duration of untreated psychosis, but did not show benefit for subsyndromal depressive symptoms.
Paper Details　
Original Abstract of the Article :
Antidepressants are frequently prescribed in first episode schizophrenia (FES) patients for negative symptoms or for subsyndromal depressive symptoms, but therapeutic benefit has not been established, despite evidence of efficacy in later-stage schizophrenia. We conducted a 52 week, placebo-controll...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.schres.2019.01.028

データ提供：米国国立医学図書館（NLM）

Investigating the Role of Citalopram in First-Episode Schizophrenia: A Comprehensive Trial

This study, the DECIFER trial, investigates the efficacy of citalopram as an add-on therapy for patients with first-episode schizophrenia (FES) who do not meet criteria for major depression. The 52-week, placebo-controlled trial aimed to determine whether citalopram could improve outcomes by preventing or improving negative and depressive symptoms. The study found that citalopram reduced negative symptoms, particularly in patients with a longer duration of untreated psychosis (DUP), but did not show benefit for subsyndromal depressive symptoms. While citalopram was associated with more sexual side effects, overall treatment-emergent side effects were not significantly increased compared to placebo. The findings suggest that citalopram may offer potential benefits for reducing negative symptoms in FES patients, but further research is needed to optimize its use and explore its potential in different clinical settings.

Citalopram: A Potential Aid for Negative Symptoms in FES

The study’s findings suggest that citalopram may offer a potential benefit in reducing negative symptoms in first-episode schizophrenia (FES) patients, particularly those with a longer duration of untreated psychosis (DUP). This is a significant observation, as it could lead to improved symptom management and potentially enhanced quality of life for individuals with FES.

Navigating Mental Health: A Journey of Understanding and Support

Mental health conditions, like schizophrenia, can be challenging to navigate. This study highlights the importance of ongoing research and personalized treatment approaches to address these conditions effectively. It’s like a camel finding its way through a shifting sandstorm, understanding the nuances of each individual’s journey is essential for providing the best support.

Dr. Camel's Conclusion

This study, like a desert explorer venturing into uncharted territory, unveils valuable insights into the complex world of schizophrenia. It’s a reminder that ongoing research and understanding are crucial for navigating the challenges of mental health and providing the best possible support for those affected.

Date :
  1. Date Completed 2020-08-17
  2. Date Revised 2020-08-17
Further Info :

Pubmed ID

30709746

DOI: Digital Object Identifier

10.1016/j.schres.2019.01.028

Related Literature

Article Analysis
・Side Effects of citalopram
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.